mRNA

Rethinking Pipeline Value Beyond Peak Sales Forecasts

Yuvraj — Wed, 24 Dec 2025 08:47:40 +0000

The traditional reliance on risk-adjusted Net Present Value (rNPV) and peak sales forecasts is failing to capture the true potential of modern pharmaceutical assets, particularly platform technologies. This article introduces holistic valuation frameworks like Real Options Analysis (ROA) and the Platform VISTA model, arguing for a shift toward valuing "strategic fit," "lifecycle potential," and the intangible equity of innovation engines.

The post Rethinking Pipeline Value Beyond Peak Sales Forecasts first appeared on World Pharma Today.

Building Resilient Pharma Portfolios in an Era of Scientific and Market Uncertainty

Yuvraj — Wed, 24 Dec 2025 08:26:57 +0000

Pharmaceutical companies are radically redesigning portfolio strategies to survive a "triple threat" environment of scientific complexity, regulatory upheaval like the IRA, and capital scarcity. This analysis explores the shift from efficiency-driven models to resilience-first frameworks, detailing how leaders are embedding optionality into pipelines, embracing modality agnosticism, and using dynamic resource allocation to thrive amidst volatility.

The post Building Resilient Pharma Portfolios in an Era of Scientific and Market Uncertainty first appeared on World Pharma Today.

Onshoring of Drug Product Manufacturing to Massachusetts

Yuvraj — Tue, 25 Nov 2025 13:30:19 +0000

Moderna is set to expand its US manufacturing capabilities through the onshoring of drug product manufacturing to its present Moderna Technology Center – MTC located Norwood, Massachusetts, in a move that involves an investment of over $140m. By way of this onshoring, the company is now going to operate complete end-to-end mRNA medicine manufacturing throughout the country. It […]

The post Onshoring of Drug Product Manufacturing to Massachusetts first appeared on World Pharma Today.